Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNIFER M BASHOUR

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1922032911
CMS profile
314462
Location
IRVING, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$335.35

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $170.13 1
Food and Beverage $165.22 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Alnylam Pharmaceuticals Inc. $335.35 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNIFER M BASHOUR

NPI 1922032911 · CMS profile ID 314462

Allopathic & Osteopathic Physicians / Internal Medicine

IRVING, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922032911?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNIFER M BASHOUR, NPI 1922032911, CMS profile ID 314462. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922032911?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JENNIFER M BASHOUR, NPI 1922032911, CMS profile ID 314462. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922032911?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JENNIFER M BASHOUR, NPI 1922032911, CMS profile ID 314462, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1922032911?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $335.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alnylam Pharmaceuticals Inc. $70.5008/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926091523 CMS
Alnylam Pharmaceuticals Inc. $94.7208/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926091525 CMS
Alnylam Pharmaceuticals Inc. $170.1308/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926091527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $335.35 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $575,063.70 36
PY2024 Principal investigator $115,453.31 6
PY2023 Principal investigator $54,396.84 174
PY2022 Principal investigator $8,309.00 200
PY2021 Principal investigator $29,842.65 8
PY2020 Principal investigator $241.38 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

200 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099295
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099289
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099299
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910099457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099553
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910099557
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099215
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127969
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099245
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Synexus Research-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910099269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127601
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 03/28/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 03/22/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 03/22/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 03/22/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 03/22/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $600.00 03/22/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910127803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 03/14/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 03/14/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 03/14/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 03/14/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 03/14/2022 Non-covered Recipient Entity
Synexus Clinical Research US,Inc.-Dallas
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910127637